Phase 2 data from vebreltinib (APL-101), a highly selective cMet inhibitor, in patients with NSCLC with MET exon14 skipping mutation…
Provides Initial $59 Million and up to $168 Million Contingent on MilestonesNATICK, Mass., Sept. 28, 2023 (GLOBE NEWSWIRE) -- ModeX…
AI-driven literature extraction for thousands of rare disease genes fortifies and extends QIAGEN’s proprietary, human-certified content, providing complete bibliographic coverage…
CHATHAM, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical…
Positive Conclusion Reached in Immunomodulator I Patent OppositionPatent opposition hearing cancelledLONDON, UK / ACCESSWIRE / September 29, 2023 / Poolbeg…
BOTHELL, Wash. (September 28, 2023) – Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), announces dosing of the first…
EDMONTON, Alberta--(BUSINESS WIRE)--BioAlberta has published its 2023 State of the Industry (SOI) report. This year’s report includes new insights and…
Beilinson Hospital in Israel used Nanox.AI’s HealthCCSng solution to conduct study on routine chest CT scans to assess impact of…
Intent-to-treat population shows 9-month OS improvement over control arm Subgroup of patients treated with IMNN-001 + PARPi shows meaningful PFS…
BOTHELL, Wash., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”), announces dosing of…